IonQ's $1.2 Billion Backlog Is Only Half the Story as Analysts Trim Targets

IonQ closed its Elisity acquisition on Wednesday, paying entirely in stock, and the price tag tells you plenty about how management is choosing to fund its expansion. The quantum computing group issued common shares worth $1.15 billion to the sellers, with up to $150 million more contingent on revenue milestones running through January 2028. That structure puts execution squarely on the hook: the deal only looks cheap if the acquired business delivers.

The same week brought a second transaction with a very different shape. IonQ announced a partnership with QuantumCT under which the organization will buy access to IonQ quantum computers on behalf of Connecticut institutions, covering more than 150 hours of cloud runtime. One deal spends equity to widen the business; the other sells access to systems IonQ already runs.

What the quarter actually showed

The numbers released yesterday give the growth story real substance. Revenue in the third quarter of 2026 reached $173.8 million, up 336% from a year earlier. Management also lifted its full-year 2026 revenue guidance to a range of $505 million to $515 million.

The profit picture is less comfortable. IonQ reported an adjusted EBITDA loss of $133.6 million, a reminder that the top line is expanding faster than the cost base is shrinking.

Remaining performance obligations — contracted work not yet booked as revenue — now stand at $1.2 billion, more than double the prior level. Against a full-year revenue target of roughly half a billion dollars, that backlog is the single most important number investors can track. It represents work IonQ has already won, provided it can deliver.

Two analysts, one direction

Wedbush confirmed its "Outperform" rating yesterday but cut its price target to $50 from $75, citing lower sector-wide growth assumptions for the next two years. Earlier in the week, B. Riley had already taken its target down to $75 from $100 while keeping its buy recommendation.

Both houses stayed positive on the company and both reduced the price they are willing to put on it. That combination sets a higher bar: the bullish case survives, but it now has less room to run on valuation alone.

The broader tape did IonQ no favors. The stock fell 10% yesterday as a selloff in chip and AI names spread into quantum computing, with media reports pointing to post-midterm election pressure across the sector. Shares were up 6.2% in premarket trading today.

Capital is not the constraint

Balance sheet strength gives management room to maneuver. IonQ completed a $2.0 billion equity financing on October 16, and on a pro forma basis — including that raise — cash, cash equivalents and investments totaled $3.7 billion.

That is a substantial war chest for a company at this stage. It matters only to the extent it gets converted into delivered contracts, which is why the QuantumCT agreement and the Elisity integration are the right things to watch. Rising revenue paired with a growing backlog would signal that IonQ is both working through existing obligations and laying the groundwork for the next layer of growth.

The test ahead

The investment case now rests on a straightforward transition: turning contractual commitments into recognized revenue while making progress on losses. Guidance has been raised, the backlog has more than doubled, and the balance sheet can support years of spending. What has not yet been demonstrated is the pace at which that capacity becomes business.

If contract execution stalls, the equity issued for Elisity and the capital raised in October will face sharper scrutiny. If it holds, the trimmed targets from Wedbush and B. Riley will look like caution rather than doubt.